Product & Ingredient Identity Documents

Telling FSSAI Exactly What You Are Asking Them to Approve

By Dr. Ashwini Kumar

Founder & CEO, CE Group of Companies  |  Forbes Business Council Member

Regulatory Affairs Expert | Clinical Trials Advisor | Medtech & Food Regulatory Consultant

 

Identity Is the Starting Point of Every Risk Assessment

Before FSSAI’s Scientific Panel can assess whether your ingredient or product is safe, it needs to know precisely what it is. Section B — Product and Ingredient Identity — provides that foundation. It tells the Panel what substance they are evaluating, where it comes from, how it is made, and how you propose to use it in the Indian market.

This sounds straightforward. In practice, it is where many applications create problems for themselves — not through scientific weakness, but through imprecision. A vague formulation description, an unspecified botanical source, a manufacturing process described in two sentences — each of these generates Panel queries that could have been avoided with careful document preparation.

The principle behind Section B is simple: if the Panel cannot identify what you are asking them to approve, they cannot approve it. Precision here is not bureaucratic formality — it is the scientific foundation on which your entire safety case rests.

Section B Document Checklist

#	Document / Data Element	Expert Note
B1	Complete product formulation — all ingredients with % w/w concentration	No ‘proprietary blend’ masking. Every ingredient, every concentration. Scientific Panel cannot assess safety without this.
B2	Full chemical identity — IUPAC name, CAS number, molecular formula, structural formula	For complex botanical extracts: characterise the active marker compound(s) in addition to the bulk extract.
B3	Source details — biological origin, taxonomic classification, country of origin, plant part used	For plant-derived ingredients: genus, species, and plant part (root, leaf, seed) must be specified. Vague ‘herbal extract’ descriptions are rejected.
B4	Manufacturing / production process with flow diagram	Include extraction solvent, concentration steps, purification method, drying technology. Novel process technology must be explicitly described.
B5	Proposed conditions of use — dosage, format, target population, frequency, contraindications	Dosage must be evidence-based and consistent with safety data. Overstated dosages relative to NOAEL are a common Panel query trigger.
B6	Draft India-compliant label	Submitted at Section B stage as identity reference.

Table 1

The Four Identity Elements That Most Affect Panel Review Speed

Formulation Completeness — No Proprietary Blends

For Form II (finished product) applications, the complete formulation must list every ingredient with its precise percentage by weight (% w/w). FSSAI’s Scientific Panel cannot conduct exposure assessment or risk characterisation if ingredient concentrations are masked as ‘proprietary blends’ or ‘botanical complex.’

If your formulation contains ingredients you consider commercially confidential, FSSAI has a provision for confidential data submission — but the Panel still receives the full formulation for scientific review. Discuss confidentiality treatment with your regulatory consultant before filing.

Chemical Identity Precision for Novel Ingredients

For Form I applications, chemical identity must be specified to the level that allows unambiguous identification. For synthetic or semi-synthetic compounds — NR, trans-Resveratrol — this means IUPAC name, CAS registry number, molecular formula, and structural diagram. For botanical extracts, identify the plant by genus and species (using accepted botanical nomenclature), the plant part used, the extraction solvent, and the primary active marker compound(s) with their typical concentration range in the extract.

A submission that describes an ingredient as ‘plant extract’ or ‘natural compound’ without this specificity will receive an identity query from the Panel in the first review cycle — adding weeks or months to your timeline unnecessarily.

Manufacturing Process — More Detail Than You Think Is Needed

The manufacturing process description is one of the most consistently underprepared elements of Section B. The Panel needs to understand the process because it determines what contaminants, residues, or degradation products may be present in the final ingredient.

For extracted ingredients: identify the extraction solvent (water, ethanol, CO₂), concentration technology (spray dry, freeze dry), and any purification steps. For fermentation-derived ingredients: identify the production organism, fermentation conditions, and downstream processing. For novel technology products (UV-treated, enzyme-modified, bioengineered): describe each technology step and its purpose. Attach a process flow diagram — a visual summary aids the Panel and reduces the risk of misinterpretation.

Conditions of Use — Match Your Safety Data

The proposed conditions of use — dosage per day, target population, product format, consumption frequency — must be consistent with the safety data submitted in Section D. If your sub-chronic toxicity study establishes a NOAEL at a certain dose in rodents, and your proposed human daily intake at the recommended dosage does not provide an adequate safety margin the Panel may seek clarification regarding the dosage.

Set your proposed dosage based on the evidence — not on what your global label says. India’s conditions of use may differ from your US or EU approved dosage, and that is a normal and manageable outcome of the regulatory process.

A Note on Botanical Ingredients — Taxonomic Precision Matters

India has a rich tradition of botanical and Ayurvedic ingredients, and FSSAI’s Scientific Panels include experts in this area. For botanical ingredients, taxonomic precision is both a scientific requirement and a credibility signal. Use the accepted Latin binomial (genus species), specify the authority (e.g., L. for Linnaeus), and confirm that the taxon name aligns with current accepted nomenclature in the Plant List or World Flora Online databases.

If your botanical ingredient has a traditional Indian name or Ayurvedic identity — Ashwagandha (Withania somnifera), Amla (Phyllanthus emblica), Brahmi (Bacopa monnieri) — state it explicitly. A documented history of traditional Indian use significantly strengthens the Section E (consumption history) component of your dossier.

How CliniExperts Can Help

CliniExperts and Innovation Bridge Healthcare (IBH) provide end-to-end NSF dossier preparation and FSSAI e-PAAS filing support. Whether you need a pre-filing gap analysis, full dossier build, or Scientific Panel query management — our regulatory team is here.

Connect: www.cliniexperts.com  |  innovationbridgehealthcare.com  |  Forbes Business Council Member|contact@cliniexperts.com